Lantheus (NASDAQ:LNTH) Stock Rating Upgraded by Truist Financial

Lantheus (NASDAQ:LNTH) was upgraded by investment analysts at Truist Financial from a “hold” rating to a “buy” rating in a report issued on Thursday, MarketBeat reports. The brokerage presently has a $80.00 price objective on the medical equipment provider’s stock. Truist Financial’s target price points to a potential upside of 20.08% from the company’s previous close.

Several other research firms have also issued reports on LNTH. The Goldman Sachs Group set a $77.00 target price on shares of Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th. B. Riley dropped their price target on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. TD Cowen reduced their price objective on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, September 15th. Finally, Weiss Ratings lowered shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and an average target price of $77.33.

Lantheus Stock Up 5.6%

Shares of LNTH traded up $3.52 during mid-day trading on Thursday, hitting $66.62. 1,549,880 shares of the company traded hands, compared to its average volume of 973,316. The business has a 50 day moving average of $56.57 and a 200 day moving average of $63.18. The company has a market capitalization of $4.42 billion, a PE ratio of 27.99 and a beta of -0.10. Lantheus has a 1-year low of $47.25 and a 1-year high of $111.29. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The business had revenue of $92.51 million for the quarter. Equities research analysts anticipate that Lantheus will post 6.01 EPS for the current year.

Hedge Funds Weigh In On Lantheus

A number of institutional investors have recently added to or reduced their stakes in LNTH. HighTower Advisors LLC grew its holdings in Lantheus by 107.8% in the 1st quarter. HighTower Advisors LLC now owns 4,797 shares of the medical equipment provider’s stock valued at $468,000 after buying an additional 2,488 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Lantheus by 204.8% in the first quarter. Russell Investments Group Ltd. now owns 51,682 shares of the medical equipment provider’s stock valued at $5,044,000 after purchasing an additional 34,727 shares during the period. Dimensional Fund Advisors LP increased its position in Lantheus by 2.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider’s stock worth $134,534,000 after purchasing an additional 31,454 shares during the last quarter. Aberdeen Group plc raised its stake in Lantheus by 3.6% during the first quarter. Aberdeen Group plc now owns 7,416 shares of the medical equipment provider’s stock worth $724,000 after purchasing an additional 257 shares during the period. Finally, Hsbc Holdings PLC acquired a new position in Lantheus in the 1st quarter valued at about $235,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.